Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges: 2013-2024

Historic Amortization of Deferred Charges for Ani Pharmaceuticals (ANIP) over the last 12 years, with Dec 2024 value amounting to $642,000.

  • Ani Pharmaceuticals' Amortization of Deferred Charges rose 180.99% to $340,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 24.80%. This contributed to the annual value of $642,000 for FY2024, which is 83.63% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $642,000 for FY2024, which was down 83.63% from $3.9 million recorded in FY2023.
  • Ani Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $4.0 million during FY2022, with a 5-year trough of $642,000 in FY2024.
  • In the last 3 years, Ani Pharmaceuticals' Amortization of Deferred Charges had a median value of $3.9 million in 2023 and averaged $2.8 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 57.68% in 2022, then tumbled by 83.63% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $1.9 million in 2020, then skyrocketed by 33.90% to $2.5 million in 2021, then soared by 57.68% to $4.0 million in 2022, then dropped by 0.98% to $3.9 million in 2023, then slumped by 83.63% to $642,000 in 2024.